The End Tuberculosis Now Act of 2026 authorizes U.S. government assistance to combat tuberculosis globally through prevention, diagnosis, treatment, and vaccine development programs, with particular focus on high-burden countries and drug-resistant TB cases. The bill establishes specific targets for 2027 through 2030, including reducing TB incidence by 80 percent and mortality by 90 percent compared to 2015 levels, diagnosing and treating 90 percent of TB cases, achieving 90 percent treatment success rates, and providing preventive treatment to 30 million people. The President is directed to prioritize efforts that strengthen health systems, support public-private partnerships, and research TB diagnostics and vaccines. The law requires annual congressional reports on implementation progress and outcomes, including data on screening, diagnosis, treatment completion, and research gaps, with a Government Accountability Office evaluation due after four years. All reporting requirements expire on January 1, 2033.